Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.78 | N/A | +21.09% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.78 | N/A | +21.09% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the earnings beat on EPS. They emphasized their commitment to maintaining shareholder value.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our shareholders.
Pfizer's strong EPS performance indicates effective cost management and operational efficiency, contributing to a positive stock reaction of 3.14%. Investors may view this earnings beat as a sign of resilience in a challenging market. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STRYKER CORP
Oct 31, 2022